Edition:
United States

Apricus Biosciences Inc (APRI.O)

APRI.O on Consolidated Issue listed on NASDAQ Capital Market

1.60USD
17 Nov 2017
Change (% chg)

$-0.02 (-1.23%)
Prev Close
$1.62
Open
$1.63
Day's High
$1.66
Day's Low
$1.58
Volume
72,013
Avg. Vol
318,846
52-wk High
$4.07
52-wk Low
$0.86

Latest Key Developments (Source: Significant Developments)

Apricus Biosciences files for mixed shelf of up to $100 million
Thursday, 2 Nov 2017 05:36pm EDT 

Nov 2 (Reuters) - Apricus Biosciences Inc :Apricus Biosciences files for mixed shelf of up to $100 million - SEC filing.  Full Article

Apricus Biosciences reports Q3 loss per share $0.29
Thursday, 2 Nov 2017 04:01pm EDT 

Nov 2 (Reuters) - Apricus Biosciences Inc :Apricus Biosciences Inc provides corporate update and third quarter 2017 financial results.Q3 loss per share $0.29.Apricus Biosciences Inc - ‍as of September 30, 2017, company's cash totaled $8.5 million, compared to $2.1 million as of December 31, 2016​.  Full Article

Apricus Biosciences files for resale of up to 3.3 mln of common stock by selling stockholders
Monday, 25 Sep 2017 05:06pm EDT 

Sept 25 (Reuters) - Apricus Biosciences Inc :Apricus Biosciences Inc files for resale of up to 3.3 million of common stock by selling stockholders - SEC Filing.  Full Article

Apricus Biosciences says Armistice Capital reports a 9.6 pct passive stake in co
Wednesday, 20 Sep 2017 05:22pm EDT 

Sept 21 (Reuters) - Apricus Biosciences Inc :Armistice Capital LLC reports 9.6 percent passive stake in Apricus Biosciences Inc, as of September 10, 2017 - SEC filing .‍​.  Full Article

Apricus Biosciences announces $3.7 million private placement priced at-the-market
Monday, 11 Sep 2017 07:00am EDT 

Sept 11 (Reuters) - Apricus Biosciences Inc :Apricus Biosciences announces $3.7 million private placement priced at-the-market.Apricus Biosciences Inc - co to sell an aggregate of 2.13 million shares of common stock at $1.7275 per share.  Full Article

Apricus Biosciences announces FDA acknowledgement of Vitaros class 2 NDA resubmission
Thursday, 31 Aug 2017 07:00am EDT 

Aug 31 (Reuters) - Apricus Biosciences Inc :Apricus Biosciences announces FDA acknowledgement of Vitaros class 2 NDA resubmission.Apricus Biosciences Inc - ‍PDUFA goal date for completion of FDA's review of Vitaros NDA is set for February 17, 2018​.  Full Article

Apricus Biosciences Q2 loss per share $0.13
Wednesday, 2 Aug 2017 04:01pm EDT 

Aug 2 (Reuters) - Apricus Biosciences Inc ::Apricus Biosciences provides corporate update and second quarter 2017 financial results.Q2 loss per share $0.13.  Full Article

Apricus Biosciences Q1 earnings per share $1.04
Thursday, 11 May 2017 04:01pm EDT 

May 11 (Reuters) - Apricus Biosciences Inc ::Apricus Biosciences provides corporate update and first quarter 2017 financial results.Q1 earnings per share $1.04.Apricus Biosciences Inc says Vitaros U.S. NDA re-submission remains on track for q3 2017.Apricus Biosciences Inc says vitaros drug-device human factor studies underway.Apricus Biosciences Inc says operations funded through Q3 of 2018.  Full Article

Apricus Biosciences reports initiation of vitaros drug-device human factors study
Thursday, 4 May 2017 07:00am EDT 

May 4 (Reuters) - Apricus Biosciences Inc :Apricus Biosciences announces the initiation of vitaros drug-device human factors study.Apricus biosciences inc- vitaros drug-device combination human factor testing study required by food and drug administration is underway.Apricus biosciences - expect study will be completed in q2 of this year and results will be incorporated into our planned vitaros nda re-submission.Apricus biosciences inc- vitaros nda re-submission remains on track for q3 of this year.  Full Article

Apricus Biosciences announces pricing of $7.0 mln public offering
Friday, 21 Apr 2017 06:00am EDT 

April 21 (Reuters) - Apricus Biosciences Inc :Apricus Biosciences announces pricing of $7.0 million public offering.Apricus Biosciences Inc - pricing of an underwritten public offering of an aggregate of 5.03 million units.Apricus Biosciences Inc says pricing of an underwritten public offering of an aggregate of 5 million units at public offering price of $1.40 per unit.  Full Article

BRIEF-Apricus Biosciences files for mixed shelf of up to $100 million

* Apricus Biosciences files for mixed shelf of up to $100 million - SEC filing Source text : (http://bit.ly/2gZ2TjB) Further company coverage: